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Abstract 
Background: Breast cancer is a heterogeneous disorder for which the underlying genetic basis remains unclear. We 
developed a method for identifying adenomatous polyposis coli (APC) mutations and we evaluated the possible asso‑
ciation between APC genetic variants and breast cancer susceptibility.
Methods: Genomic DNA was extracted from tumor and matched peripheral blood samples collected from 89 breast 
cancer patients and from peripheral blood samples collected from 50 controls. All samples were tested for mutations 
in exons 1–14 and the mutation cluster region of exon 15 by HRM analysis. All mutations were confirmed by direct 
DNA sequencing.
Results: We identified a new single nucleotide polymorphism (SNP), c.465A>G (K155K), in exon 4 and seven known 
SNPs: c.573T>C (Y191Y) in exon 5, c.1005A>G (L335L) in exon 9, c.1458T>C (Y486Y) and c.1488A>T (T496T) in exon 11, 
c.1635G>A (A545A) in exon 13, and c.4479G>A (T1493T) and c.5465T>A (V1822D) in exon 15. The following altera‑
tions were found in 2, 1, 2, and 1 patients, respectively: c.465A>G, c.573T>C, c.1005A>G, and c.1488A>T. There was no 
observed association between breast cancer risk and any of these APC SNPs.
Conclusions: APC mutations occur at a low frequency in Taiwanese breast cancer cases. HRM analysis is a powerful 
method for the detection of APC mutations in breast.
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Background
Breast cancer is a common malignancy and the leading 
cause of death from cancer among females in economi-
cally developing countries, accounting for 23  % (1.38 
million) of all new cancer cases and 14 % (458,400) of all 
cancer deaths in 2008 [1]. The incidence of breast can-
cer has been increasing in Asia [2, 3]; moreover, breast 
cancer in Asians occurs at a younger age than in Cau-
casians. To date, treatment planning for breast cancer 
patients has been based on a histologic analysis of the 
primary tumor and the expression of molecular mark-
ers such as estrogen receptor (ER), progesterone recep-
tor (PR), and human epidermal growth factor receptor 
2 (HER2). Combinations of these markers can be used 
to further subtype the tumor and guide treatment plan-
ning, including luminal A (ER+ and/or PR+; HER2−), 
luminal B (ER+ and/or PR+; HER2+), basal-like (ER−, 
PR−, and HER2−), and HER2-enriched (ER−, PR−, and 
HER2+) markers [4]. Although breast cancer survival 
has improved significantly within the last few decades, 
the need for new therapeutic strategies aimed at specific 
tumorigenic cells and their key oncogenic pathways has 
become obvious.
Like most cancers, the development of breast can-
cer is the result of accumulated mutations in oncogenes 
and tumor suppressor genes. These genes are involved in 
cell proliferation, growth, differentiation, survival, apop-
tosis, and DNA repair [5, 6]. A large number of well-
established cancer genes have been implicated in breast 
cancer development, including BRCAl, RB1, TP53, PTEN, 
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AKT1, CDH1, GATA3, and PIK3CA. Other groups of 
genes responsible for signal transduction including APC, 
ARID1A, ARID2, ASXL1, BAP1, KRAS, MAP2K4, MLL2, 
MLL3, NF1, SETD2, SF3B1, SMAD4, and STK11, have 
also been found to contain somatic mutations in tumors. 
In addition, new cancer genes that had not previously been 
implicated in the development of breast cancer have been 
found to be mutated, including ARID1B, CASP8, MAP3K1, 
MAP3K13, NCOR1, SMARCD1, and CDKN1B [7, 8].
APC, which was cloned in 1991, is located at chromo-
some 5q21-22 and contains 15 exons. Its tumor-sup-
pressing activity is thought to be based on regulation of 
the intracellular level of beta-catenin within the Wing-
less/Wnt signal transduction pathway [9]. In the absence 
of Wnts, casein kinase 1 and glycogen synthase kinase-
3-bata phosphorylate beta-catenin, causing the ubiqui-
tination and subsequent degradation of beta-catenin by 
the 26S proteasome. Conversely, when Wnt proteins are 
secreted from cells, the phosphorylation and degrada-
tion of beta-catenin is blocked, leading to its accumula-
tion. The stabilized beta-catenin then translocates to 
the nucleus, where it binds with T-cell factor/lymphoid 
enhancer-binding factor-1 to induce the expression of 
downstream target genes. The mutation of APC may 
cause constitutive stimulation of the Wingless/Wnt sig-
nal transduction pathway, promoting the accumulation 
of beta-catenin in the cytoplasm and leading to aberrant 
cellular proliferation. Therefore, APC is a negative regu-
lator of the Wingless/Wnt signal transduction pathway. 
The Wingless/Wnt signal transduction pathway may 
represent a novel therapeutic target for the treatment of 
triple-negative breast cancer (ER, PR, and HER 2-nega-
tive breast cancer) [10]. In this regard, mutations in APC 
in patients with breast cancer are of particular interest.
APC mutations are a major contributing factor to colo-
rectal cancer. In breast cancer patients, the overall APC 
mutational rate ranges from 0.4 to 18  % [11, 12]. We 
used high-resolution melting (HRM) analysis and direct 
sequencing to screen exons 1–14 and part of exon 15, 
including the mutation cluster region (MCR) (codons 
1286–1513), of APC in breast cancer tissues. The aim of 
this study was to understand the APC mutation status in 
a Taiwanese cohort of breast cancer patients.
Results
HRM analysis of APC
The clinical characteristics of the breast cancer patients 
enrolled in this study, including mean age, age range, and 
receptor status, are presented in Table 1.
The APC gene mutations identified in the 89 patients 
and 50 controls by HRM analysis are summarized 
in Table  2. Eight single-nucleotide alterations were 
detected in the cancerous tissues of the patients, 
including c.465A>G in exon 4 (Fig. 1), c.573T>C in exon 
5, c.1005A>G in exon 9, c.1458T>C and c.1488A>T 
in exon 11, c.1635G>A in exon 13, and c.4479G>A and 
c.5465T>A in exon 15 (Additional file  1: Figure S4, S8, 
S10, S12 and S14). HRM analysis of exons 1–3, 6–8, 10, 
12, and 14 failed to identify mutations or polymorphisms 
in these regions (Additional file 1: Figure S1-S3, S5-S7, S9, 
S11 and S13). The frequencies of the SNPs in the controls 
were 0 % for c.465A>G, c.573T>C, and c.1488A>T. The 
frequencies for c.1005A>G, c.1458C, c.1635A, c.4479A, 
and c.5465A were 1, 67, 85, 85, and 94  %, respectively, 
and therefore similar to those in the malignant tissues. 
An evaluation of the relationship between each APC 
SNP and breast cancer risk (Table  2) did not show an 
association with any of the SNPs at any of the loci.
Concordance of SNPs in paired tumor and blood samples
To determine whether c.465A>G, c.573T>C, c.1005A>G, 
and c.1488A>T were somatic or germline abnormali-
ties, we investigated the concordance between geno-
types from all 89 paired tumor and blood samples. The 
data indicated a 97.75  % (87/89) concordance between 
tumor and blood samples, except for a discrepancy in 
two samples for c.573T>C and c.1488A>T, in which the 
mutations were somatic and were detected in the tumor 
tissues but not in the blood sample.
Discussion
Mutations in APC have been found in several cancers, 
including colorectal [13], pancreatic [14], and hepa-
tocellular [15], but they are reported to be much rarer 
in breast cancer. The first report of APC mutations in 
breast cancer was published by Kashiwaba et  al. [16], 
Table 1 Clinical characteristics of  the breast cancer 
patients
a TNM stage based on the sixth edition of the American Joint Committee on 
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who detected a mutation rate of 6 % (2 of 31) in primary 
breast carcinoma samples using PCR followed by restric-
tion fragment length polymorphism (RFLP) and single-
strand conformation polymorphism (SSCP) analyses. 
Sorlie et  al. [11] studied mutations in exon 15 using a 
protein truncation test (PTT). They reported a frameshift 
mutation at nucleotide 4678 in one patient (1 of 227). 
Furuuchi et  al. [12] screened almost the entire coding 
region using a yeast-based assay. They reported a muta-
tion rate of 18 % (13 of 70) in primary breast cancers; the 
mutations included five nonsense mutations, five single 
base pair deletions, and five single base pair insertions. 
Until now, their study had the highest reported mutation 
rate in breast cancer. Hayes et al. [17] analyzed exon 15 
in 27 metaplastic carcinomas by direct DNA sequenc-
ing and found one mutation in two samples (7.4 %). Kan 
et  al. [18] used mismatch repair detection (MRD) tech-
nology to identify somatic mutations in 441 tumors, 
including 183 breast cancers. They found three mutations 
in three breast tissue samples (1.6 %). Stephens et al. [8] 
used whole exome sequencing to detect somatic altera-
tions in 100 patients. They found two mutations in two 
breast samples (2  %). The above-mentioned mutations 
were unique. In the present study, among the eight APC 
SNPs detected, seven were silent in the 89 breast cancer 
samples. Of those, five were also found in the control 
population, one was present in both blood and cancerous 
tissue, and two (c.573T>C and c.1488A>T) were somatic 
mutations detected in cancerous tissues only and not in 
patients’ blood cells. These results suggest that APC does 
not play an important role in the development of breast 
cancer in the Taiwanese population, although the APC 
mutation rate was higher in breast cancer patients than 
in controls. However, a limitation of our study was that 
we did not comprehensively evaluate all of the exons in 
the control samples.
The methods typically used to detect APC mutations 
have some weakness. PCR-RFLP and PCR-SSCP are sim-
ple to perform but require gel electrophoresis to separate 
the PCR amplicons; they are therefore not suitable for 
Table 2 Single nucleotide alterations in APC identified in breast cancers (n = 89) and controls (n = 50) using high resolu-
tion melting analysis
*  P value by Fisher’s exact test when the cell expectation was less than five
Position in gene Nucleotide loca-















Exon 4 c.465A>G K155K
Allele A 176 (98.88) 100 (100) 0.5377*
Allele G 2 (1.12) 0 (0)
Exon 5 c.573T>C Y191Y rs185154886
Allele T 100 177 (99.44) 100 (100) 1.000*
Allele C 0 1 (0.56) 0 (0)
Exon 9 c.1005A>G L335L rs3797704
Allele A 100 176 (98.88) 99 (99) 1.000*
Allele G 0 2 (1.12) 1 (1)
Exon 11 c.1458T>C Y486Y rs2229992
Allele T 32.52 52 (29.2) 33 (33) 0.511
Allele C 67.48 126 (70.8) 67 (67)
Exon 11 c.1488A>T T496T rs9282599
Allele A 99.51 177 (99.44) 100 (100) 1.000*
Allele T 0.49 1 (0.56) 0 (0)
Exon 13 c.1635G>A A545A rs351771
Allele G 18.93 29 (16.3) 15 (15) 0.777
Allele A 81.07 149 (83.7) 85 (85)
Exon 15 c.4479G>A T1493T rs41115
Allele G 18.93 24 (13.5) 15 (15) 0.727
Allele A 81.07 154 (86.5) 85 (85)
Exon 15 c.5465T>A V1822D rs459552
Allele T 9.22 14 (7.9) 6 (6.0) 0.564
Allele A 90.78 164 (92.1) 94 (94.0)
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investigating large genes with many exons, such as APC, 
or a large number of samples. In addition, PCR-RFLP 
can only detect known mutations. PTT requires the use 
of radioactive labeling for protein detection, after which 
the DNA from samples with positive PTT results is 
sequenced. The yeast colorimetric assay consists of four 
steps: PCR, homologous recombination, fusion protein 
expression, and a colorimetric assay. The MRD method is 
a robust and cost-effective, but it is not efficient in detect-
ing insertions/deletions. Exome- or APC-specific target 
sequencing using next-generation sequencing requires 
expensive equipment and bioinformatic analysis; its clini-
cal application is therefore limited.
Compared with the above-mentioned molecular diag-
nostic methods, HRM analysis is relatively cost-effective 
and technically feasible. Although HRM analysis repre-
sents the next generation of mutation scanning technol-
ogy, it also has several limitations [19, 20]. For example, 
many homozygous variants and small insertions/dele-
tions are more difficult to detect by HRM analysis and 
may produce only small differences in melting tempera-
ture (TM). This will affect the accuracy of genotyping 
which depends on the temperature resolution capability 
of the instruction. Instrument resolution is of particular 
concern in the case of thermal block instruments with 96 
or 384 wells. In this study, we failed to identify the sub-
stitution of a single nucleotide in exons 11 (c.1458T>C), 
13 (1635G>A), and 15 (c.4479G>A and c.5465T>A) by 
HRM analysis because homozygotes could not be dis-
tinguished. To solve this problem, homozygous samples 
were mixed with a known genotype before HRM analy-
sis. When an equal amount of wild-type DNA was added, 
the wild-type samples remained the same in the normal-
ized and temperature-shifted difference plots, while the 
homozygous mutant samples exhibited heteroduplex for-
mation; however, this approach doubled the amount of 
work.
Although HRM analysis could be used to identify het-
erozygotes, different heterozygotes may produce simi-
lar melting curves to each other. In this study, the exon 
Fig. 1 HRM assays and sequence traces for APC exon 4. a Difference plot showed two different melting profiles, wild‑type (WT) samples was blue, 
mutation in other colors. Direct DNA sequencing confirmed the b WT and the presence of the APC exon 4 mutation: c c.465A>G
Page 5 of 6Chang et al. Cancer Cell Int  (2016) 16:23 
11 amplicon was found to contain one SNP, c.1458T>C 
(p.Y486Y; rs2229992) and one mutation, c.1488A>T 
(p.T496T; rs9282599). Our HRM analysis was successful 
in distinguishing variant-specific heterozygosity. Tindall 
et  al. [21] also demonstrated that different heterozy-
gotes were distinguishable by HRM analysis. Unfortu-
nately, HRM analysis is unable to identify which codon 
is mutated; therefore, direct DNA sequencing should be 
performed to confirm the position of the mutation when 
different heterozygotes produce highly similar melting 
curves. In addition, HRM analysis cannot detect muta-
tions surrounding an entire exon if the exon is too large 
or if entire exons and genes have been deleted. This 
would require the design of primer pairs that surround 
the entire exon. Amplicon length influences the sensi-
tivity of HRM analysis, with amplicons of 100–300 base 
pairs considered to be optimal. The shorter the ampli-
con, the greater the Tm differences among genotypes 
and therefore the better the differentiation between 
mutant and non-mutant samples. Moreover, long ampli-
cons may contain more melting domains, leading to 
rather complex melting profiles. Factors that affect the 
melting behavior of double-stranded (ds) DNA include 
the MgCl2 concentration and the quality and quantity of 
the DNA. The amounts of DNA in the samples should 
not differ significantly, in order to achieve similar thresh-
old cycles.
The four APC SNPs (c.1458T>C, c.1635G>A, 
c.4479G>A, and c.5465T>A) had a minor allele fre-
quency of 29.21, 16.29, 13.48, and 7.87  %, respectively. 
The allele frequencies were similar to those seen in the 
phase 3 data of the 1000 Genomes Project (Table  2). 
This is the first investigation of the association between 
SNPs in APC and breast cancer. Previous studies have 
addressed the association between SNPs in APC and 
colorectal cancer risk [22, 23]. c.3920T>A is the most 
common APC variant described in breast cancer. Pre-
vious studies investigated the association between this 
variant and susceptibility to breast cancer among Ashke-
nazi Jews [24, 25]; however, no significant contribution to 
breast cancer susceptibility was found for the four SNPs. 
However, large-scale studies are needed to validate these 
findings.
Conclusions
Our results indicate that the prevalence of APC muta-
tions in Taiwanese breast cancer patients is rare, simi-
lar to other populations. It can thus be concluded that, 
at least in these patients, the APC gene does not play an 
important role in the oncogenesis of breast cancer. We 
also identified two somatic APC mutations. HRM analy-
sis is a rapid and cost-effective method for the mutational 
analysis of APC.
Methods
Sample preparation and DNA isolation
Breast tissue samples and matched peripheral blood sam-
ples from 89 breast cancer patients who had undergone 
surgery at China Medical University Hospital (Taichung 
City, Taiwan) from 2003 to 2009 were included in this 
study. The tissues were frozen immediately after surgi-
cal resection and stored in liquid nitrogen until DNA 
extraction. As controls, 50 healthy individuals were also 
recruited. Genomic DNA was extracted using a commer-
cially available kit (GE Healthcare, Little Chalfont, UK). 
The quality of the isolated genomic DNA was assessed 
using agarose gel electrophoresis, and the concentration 
was determined using a Nano-Drop-1000 spectropho-
tometer (Nano-Drop Technologies Inc., Wilmington, 
DE, USA). This study was approved by the Institutional 
Review Board of the China Medical University.
HRM analysis
PCR and a melting analysis of APC mutations were per-
formed using the LightCycler® 480, a real-time PCR 
machine with HRM and 96/384 well capacity. The primers 
used in this study were previously described [26] and were 
of standard molecular biology quality (Protech Technol-
ogy Enterprise Co., Ltd., Taipen City, Taiwan). Controls 
samples were tested for mutations in exons 4, 5, 9, 11, and 
13, and the MCR of exon 15 using HRM analysis. PCR 
was performed with ~10 ng of DNA and 0.25 μM each of 
the relevant forward and reverse primers in a total reac-
tion volume of 10  μl. Each reaction consisted of 5  μl of 
LightCycler® 480 high-resolution melting master reagent 
(Reference 04909631001; Roche Diagnostics, Basel, Swit-
zerland) and 2.5 mM MgCl2. PCR was performed under 
the following conditions: 95  °C for 10  min, followed by 
45 cycles of 95  °C for 15 s, 60  °C for 15 s, and 72  °C for 
15 s, with a melting program at 95 °C for 1 min, 40 °C for 
1 min, and 60–90 °C (25 acquisitions/°C).
Discrimination of two homozygotes was achieved by 
generating artificial heterozygotes. Before the HRM anal-
ysis, the two homozygous genotypes (1458T vs. 1458C, 
1635G vs. 1635A, 4479G vs. 4479A and 5465T vs. 5465A) 
were mixed with a known genotype (homozygous CC 
DNA, homozygous AA DNA, homozygous AA DNA and 
homozygous AA DNA, respectively).
Upon completion of the run, the samples were ana-
lyzed using the gene scanning software (version 1.5, 
Roche Diagnostics), supplied with the LightCycler® 480. 
The melting curve analysis included: the normalization of 
melting curves equal to 100 % of the initial fluorescence 
and to 0 % of the remaining fluorescence. The tempera-
ture axis of the normalized melting curves was shifted 
such that the entire dsDNA was completely denatured. 
Difference plots were obtained by subtracting the curves 
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of the wild-type and mutant DNAs and were used to 
cluster the samples into groups.
Direct DNA sequencing
To confirm the results of the HRM analysis, the same 
amplicons were sequenced. The PCR products were 
cleaned with a PCR-M™ clean-up system (Viogen, Sun-
nyvale, CA, USA). Sequencing reactions were set up 
using a BigDye Terminator, version 3.1, cycle sequencing 
kit (Applied Biosystems, Foster City, CA, USA). BigDye® 
XTerminator™ (Applied Biosystems) was used to purify the 
reaction products. Sequencing analyses were carried out on 
an ABI Prism 3130 genetic analyzer (Applied Biosystems).
Statistical analysis
All statistical analyses were carried out using the statisti-
cal software program SPSS 17.0 for Windows (SPSS, Inc., 
Chicago, IL, USA). Differences in the genotypes of breast 
cancer patients vs. controls were evaluated using a χ2 test. 
Fisher’s exact test was used when the expected number 
in any cell was <5. A P value of <0.05 was considered to 
indicate statistical significance.
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